medigraphic.com
ISSN 3061-8142 (Digital)
ISSN 0484-7903 (Impreso)

2012, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2012; 35 (S1)


Opiaceos para el tratamiento del dolor por causas diferentes al cáncer

A de Leon-Casasola Ó

Idioma: Ingles.
Referencias bibliográficas: 58
Paginas: 321-327
Archivo PDF: 143.81 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. Journal of Pain & Symptom Management 1990;5:27-32.

  2. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 1986;25:171-186.

  3. Ballantyne JD, Mao J. Opioid therapy for chronic pain. N Eng J Med 2003;349:1943-1953.

  4. Nguyen JK, Fouts MM, Kotabe SE, Lo E. The American Journal of Geriatric Pharmacotherapy 2006;4:36-41.

  5. Johnson JA, Bootman JL. Archives of Internal Medicine 1995;155:1949-1956.

  6. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Pharmacotherapy 2005;25:1636-45.

  7. de Leon-Casasola OA. Multimodal approaches to the treatment of neuropathic pain: The role of topical analgesia. J Pain Symp Manag 2007;33:356-364.

  8. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305.

  9. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-251.

  10. Acevedo JC, Amaya A, de León Casasola OA, et al. Guías para el diagnóstico y el manejo del dolor neuropático: Consenso de un grupo de expertos latinoamericanos. Rev. Iberoamericana del Dolor 2008;3:15-46.

  11. North R, Shipley J. Practice parameters for the use of spinal cord stimulation in the treatment of chronic neuropathic pain. Pain Medicine 2007;S4:S200-S275.

  12. Turner JA, Sears JM, Loesser JD. Programmable intrathecal opioid delivery systems for chronic non-cancer pain: A systematic review of effectiveness and complications. Clin J Pain 2007;23:180-195.

  13. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998;317:526-530.

  14. Bratter DC. Effects of nonsteroidals anti-inflammatory drugs on renal function: focus on cyclooxigenase-2 selective inhibition. American Journal of Medicine 1999;107:65S-70S.

  15. Silverstein FE, Faich F, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study-a randomized controlled trial. JAMA 2000;284:1247-55.

  16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.

  17. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Int Med 2000;160:777-84.

  18. Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilization of non-steroidal anti-inflammatory drugs and hospitalized heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001;57:71-5.

  19. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase 2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-6.

  20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001;345:1809-1817.

  21. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004;364:665-674.

  22. Anonymus. Diclofenac gel – Topical NSAIDs science. Drug and Therapeutics Bulletin 1991;29:95-96.

  23. Bruhlmann P, Michael BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clinical & Experimental Rheumatology 2003;21:193-198.

  24. Caldwell JR. Avinza-24 h sustained release oral morphine therapy. Expert Opinion on Pharmacotherapy 2004;5:469-472.

  25. Matsumoto AK. Oral extended-release oxymorphone: A new choice for chronic pain relief. Expert Opinion on Pharmacotherapy 2007;8:151-157.

  26. de Leon-Casasola OA. Implementing therapy with opioids in patients with cancer. Oncology Nursing Forum 2008;35(6):S1-6.

  27. Caraceni A, Martini C, Zecca E. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliative Medicine 2004;18:177-183.

  28. Payne R. Recognition and diagnosis of breakthrough pain. Pain Medicine 2007;8:S3 S7.

  29. Pasternak GW. Insights into mu opioid pharmacology. The role of mu opioid receptor subtypes. Life Sciences 2001;68:2213-2219.

  30. Pasternak GW. The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001;7:220-231.

  31. McNicol E, Horowicz–Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. The Journal of Pain 2003;4:231-256.

  32. Mercandante S, Bruera E. Opioid switching: A systematic and critical review. Cancer Treatment Reviews 2006;32:304-315.

  33. Mercandante S. Opioid rotation for cancer pain. Cancer 1999;86:1856-1866.

  34. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-805.

  35. Harris JD, de Leon-Casasola OA. Oral erythromycin and the risk of sudden death. N. Eng J Med 2005;352:301-304.

  36. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. Journal of Pharmacology and Experimental Therapeutics 1975;192:211-217.

  37. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain 2002;3:377-384.

  38. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69(3):215-232.

  39. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508.

  40. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 Suppl):S76-82.

  41. Butler SF, Budman SH, Fernandez K, et al. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004;112(1-2):65-75.

  42. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-442.

  43. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7:671-681.

  44. Adams LL, Gatchel RJ, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 2004;27:440-459.

  45. Holmes CP, Gatchel RJ, Adams LL, et al. An opioid screening instrument: long-term evaluation of the utility of the pain medication questionnaire. Pain Pract 2006;6:74-88.

  46. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.

  47. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995;34:667-670.

  48. Rogers JF, Nafziger AN, Bertino JS, Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002;113:746-750.

  49. Rheem A, Totah P, Sheffels TR, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363–74.

  50. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 2008;4:77-91.

  51. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105(1-2):231-238.

  52. Supernaw RB. CYP2D6 and the efficacy of codeine and codeine-like drugs. American Journal of Pain Management 2001;11:30-31.

  53. Suzuki R, Porreca F, Dickenson AH. Evidence for spinal dorsal horn hyperexcitability in rats following sustained morphine exposure. Neurosci Lett 2006;407:156-161.

  54. Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-775.

  55. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213-217.

  56. Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain 1993;55:171-181.

  57. Marek P, Ben-Eliyahu S, Vaccarino AL, et al. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res 1991;558:163-165.

  58. Stockler M, Vardy J, Pillai A, et al. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-3394.




2020     |     www.medigraphic.com